{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.2","upperLimit":"67.8","value":"64.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1177"}],"units":"Participants"}],"description":"EFS for patients receiving RA + Immunotherapy following the cessation of the randomized portion of the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease","id":"OG000","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"Eligible patients non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease.","reportingStatus":"POSTED","timeFrame":"Three years","title":"Event-Free Survival (EFS) of Patients From the Non-randomized Portion of the Trial","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}